nodes	percent_of_prediction	percent_of_DWPC	metapath
Dapagliflozin—ABCB1—peripheral nervous system neoplasm	0.28	1	CbGaD
Dapagliflozin—UGT2B7—Epirubicin—peripheral nervous system neoplasm	0.0769	0.145	CbGbCtD
Dapagliflozin—CYP2A6—Tretinoin—peripheral nervous system neoplasm	0.0731	0.138	CbGbCtD
Dapagliflozin—CYP1A1—Tretinoin—peripheral nervous system neoplasm	0.0625	0.118	CbGbCtD
Dapagliflozin—CYP1A1—Dacarbazine—peripheral nervous system neoplasm	0.0537	0.101	CbGbCtD
Dapagliflozin—CYP1A2—Alitretinoin—peripheral nervous system neoplasm	0.03	0.0565	CbGbCtD
Dapagliflozin—ABCB1—Topotecan—peripheral nervous system neoplasm	0.0262	0.0494	CbGbCtD
Dapagliflozin—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.0262	0.0494	CbGbCtD
Dapagliflozin—CYP2C9—Tretinoin—peripheral nervous system neoplasm	0.0251	0.0473	CbGbCtD
Dapagliflozin—CYP1A2—Dacarbazine—peripheral nervous system neoplasm	0.024	0.0452	CbGbCtD
Dapagliflozin—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.0182	0.0342	CbGbCtD
Dapagliflozin—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.0157	0.0296	CbGbCtD
Dapagliflozin—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.0146	0.0275	CbGbCtD
Dapagliflozin—CYP1A2—Etoposide—peripheral nervous system neoplasm	0.0117	0.0221	CbGbCtD
Dapagliflozin—ABCB1—Vincristine—peripheral nervous system neoplasm	0.0112	0.0211	CbGbCtD
Dapagliflozin—CYP2C9—Cisplatin—peripheral nervous system neoplasm	0.0108	0.0203	CbGbCtD
Dapagliflozin—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.0104	0.0197	CbGbCtD
Dapagliflozin—ABCB1—Etoposide—peripheral nervous system neoplasm	0.0103	0.0193	CbGbCtD
Dapagliflozin—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.007	0.0132	CbGbCtD
Dapagliflozin—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.00671	0.0126	CbGbCtD
Dapagliflozin—CYP2D6—Doxorubicin—peripheral nervous system neoplasm	0.0066	0.0124	CbGbCtD
Dapagliflozin—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.00615	0.0116	CbGbCtD
Dapagliflozin—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.0042	0.00789	CbGbCtD
Dapagliflozin—Canagliflozin—ABCB1—peripheral nervous system neoplasm	0.00249	1	CrCbGaD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Isotretinoin—peripheral nervous system neoplasm	0.000356	0.00249	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Tretinoin—peripheral nervous system neoplasm	0.000356	0.00249	CcSEcCtD
Dapagliflozin—Discomfort—Tretinoin—peripheral nervous system neoplasm	0.000354	0.00247	CcSEcCtD
Dapagliflozin—Discomfort—Isotretinoin—peripheral nervous system neoplasm	0.000354	0.00247	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Melphalan—peripheral nervous system neoplasm	0.000351	0.00245	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Vincristine—peripheral nervous system neoplasm	0.000349	0.00244	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Vincristine—peripheral nervous system neoplasm	0.000347	0.00242	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Topotecan—peripheral nervous system neoplasm	0.000346	0.00242	CcSEcCtD
Dapagliflozin—Urethral disorder—Vincristine—peripheral nervous system neoplasm	0.000346	0.00242	CcSEcCtD
Dapagliflozin—Neoplasm malignant—Doxorubicin—peripheral nervous system neoplasm	0.000346	0.00242	CcSEcCtD
Dapagliflozin—Nocturia—Epirubicin—peripheral nervous system neoplasm	0.000344	0.0024	CcSEcCtD
Dapagliflozin—Infection—Topotecan—peripheral nervous system neoplasm	0.000344	0.0024	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Tretinoin—peripheral nervous system neoplasm	0.000344	0.0024	CcSEcCtD
Dapagliflozin—Oedema—Isotretinoin—peripheral nervous system neoplasm	0.000344	0.0024	CcSEcCtD
Dapagliflozin—Oedema—Tretinoin—peripheral nervous system neoplasm	0.000344	0.0024	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Isotretinoin—peripheral nervous system neoplasm	0.000344	0.0024	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Cisplatin—peripheral nervous system neoplasm	0.000343	0.0024	CcSEcCtD
Dapagliflozin—Renal failure—Cisplatin—peripheral nervous system neoplasm	0.000342	0.00239	CcSEcCtD
Dapagliflozin—Infection—Tretinoin—peripheral nervous system neoplasm	0.000341	0.00238	CcSEcCtD
Dapagliflozin—Infection—Isotretinoin—peripheral nervous system neoplasm	0.000341	0.00238	CcSEcCtD
Dapagliflozin—Myocardial infarction—Cisplatin—peripheral nervous system neoplasm	0.000341	0.00238	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Melphalan—peripheral nervous system neoplasm	0.000339	0.00237	CcSEcCtD
Dapagliflozin—Oedema—Melphalan—peripheral nervous system neoplasm	0.000339	0.00237	CcSEcCtD
Dapagliflozin—Extravasation—Doxorubicin—peripheral nervous system neoplasm	0.000339	0.00237	CcSEcCtD
Dapagliflozin—Infection—Melphalan—peripheral nervous system neoplasm	0.000337	0.00235	CcSEcCtD
Dapagliflozin—Skin disorder—Topotecan—peripheral nervous system neoplasm	0.000336	0.00235	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Topotecan—peripheral nervous system neoplasm	0.000335	0.00234	CcSEcCtD
Dapagliflozin—Skin disorder—Tretinoin—peripheral nervous system neoplasm	0.000334	0.00233	CcSEcCtD
Dapagliflozin—Skin disorder—Isotretinoin—peripheral nervous system neoplasm	0.000334	0.00233	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Tretinoin—peripheral nervous system neoplasm	0.000332	0.00232	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Isotretinoin—peripheral nervous system neoplasm	0.000332	0.00232	CcSEcCtD
Dapagliflozin—Skin disorder—Melphalan—peripheral nervous system neoplasm	0.000329	0.0023	CcSEcCtD
Dapagliflozin—SLC5A2—Carbohydrate metabolism—SLC2A1—peripheral nervous system neoplasm	0.000325	0.00761	CbGpPWpGaD
Dapagliflozin—SLC5A1—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	0.000324	0.00759	CbGpPWpGaD
Dapagliflozin—SLC5A2—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	0.000324	0.00759	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000323	0.00758	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000323	0.00758	CbGpPWpGaD
Dapagliflozin—Hypotension—Isotretinoin—peripheral nervous system neoplasm	0.000321	0.00224	CcSEcCtD
Dapagliflozin—Hypotension—Tretinoin—peripheral nervous system neoplasm	0.000321	0.00224	CcSEcCtD
Dapagliflozin—Malnutrition—Alitretinoin—peripheral nervous system neoplasm	0.000319	0.00223	CcSEcCtD
Dapagliflozin—Infestation NOS—Etoposide—peripheral nervous system neoplasm	0.000319	0.00223	CcSEcCtD
Dapagliflozin—Infestation—Etoposide—peripheral nervous system neoplasm	0.000319	0.00223	CcSEcCtD
Dapagliflozin—Nocturia—Doxorubicin—peripheral nervous system neoplasm	0.000319	0.00222	CcSEcCtD
Dapagliflozin—Hypotension—Melphalan—peripheral nervous system neoplasm	0.000317	0.00221	CcSEcCtD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—NF1—peripheral nervous system neoplasm	0.000316	0.00741	CbGpPWpGaD
Dapagliflozin—Acute coronary syndrome—Etoposide—peripheral nervous system neoplasm	0.000314	0.00219	CcSEcCtD
Dapagliflozin—Renal failure—Etoposide—peripheral nervous system neoplasm	0.000313	0.00219	CcSEcCtD
Dapagliflozin—Myocardial infarction—Etoposide—peripheral nervous system neoplasm	0.000312	0.00218	CcSEcCtD
Dapagliflozin—SLC5A2—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.000311	0.00729	CbGpPWpGaD
Dapagliflozin—SLC5A1—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.000311	0.00729	CbGpPWpGaD
Dapagliflozin—Back pain—Alitretinoin—peripheral nervous system neoplasm	0.000309	0.00216	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Cisplatin—peripheral nervous system neoplasm	0.000308	0.00215	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Cisplatin—peripheral nervous system neoplasm	0.000307	0.00214	CcSEcCtD
Dapagliflozin—Urethral disorder—Cisplatin—peripheral nervous system neoplasm	0.000306	0.00214	CcSEcCtD
Dapagliflozin—Blood urea increased—Epirubicin—peripheral nervous system neoplasm	0.000302	0.00211	CcSEcCtD
Dapagliflozin—Vaginal infection—Epirubicin—peripheral nervous system neoplasm	0.000302	0.00211	CcSEcCtD
Dapagliflozin—CYP2A6—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.000301	0.00706	CbGpPWpGaD
Dapagliflozin—Gastrointestinal disorder—Topotecan—peripheral nervous system neoplasm	0.000299	0.00209	CcSEcCtD
Dapagliflozin—SLC5A11—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	0.000298	0.00698	CbGpPWpGaD
Dapagliflozin—Back pain—Vincristine—peripheral nervous system neoplasm	0.000297	0.00208	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Tretinoin—peripheral nervous system neoplasm	0.000297	0.00207	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Isotretinoin—peripheral nervous system neoplasm	0.000297	0.00207	CcSEcCtD
Dapagliflozin—Constipation—Topotecan—peripheral nervous system neoplasm	0.000296	0.00207	CcSEcCtD
Dapagliflozin—Constipation—Tretinoin—peripheral nervous system neoplasm	0.000294	0.00205	CcSEcCtD
Dapagliflozin—Constipation—Isotretinoin—peripheral nervous system neoplasm	0.000294	0.00205	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Melphalan—peripheral nervous system neoplasm	0.000293	0.00204	CcSEcCtD
Dapagliflozin—Discomfort—Dactinomycin—peripheral nervous system neoplasm	0.000289	0.00202	CcSEcCtD
Dapagliflozin—Neoplasm—Epirubicin—peripheral nervous system neoplasm	0.000289	0.00202	CcSEcCtD
Dapagliflozin—SLC5A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000288	0.00675	CbGpPWpGaD
Dapagliflozin—CYP3A4—Irinotecan Pathway—BCHE—peripheral nervous system neoplasm	0.000284	0.00665	CbGpPWpGaD
Dapagliflozin—Urinary tract disorder—Etoposide—peripheral nervous system neoplasm	0.000283	0.00197	CcSEcCtD
Dapagliflozin—Oedema—Dactinomycin—peripheral nervous system neoplasm	0.000281	0.00196	CcSEcCtD
Dapagliflozin—Urethral disorder—Etoposide—peripheral nervous system neoplasm	0.00028	0.00196	CcSEcCtD
Dapagliflozin—Infection—Dactinomycin—peripheral nervous system neoplasm	0.000279	0.00195	CcSEcCtD
Dapagliflozin—Blood urea increased—Doxorubicin—peripheral nervous system neoplasm	0.000279	0.00195	CcSEcCtD
Dapagliflozin—Vaginal infection—Doxorubicin—peripheral nervous system neoplasm	0.000279	0.00195	CcSEcCtD
Dapagliflozin—Hypertension—Alitretinoin—peripheral nervous system neoplasm	0.000276	0.00192	CcSEcCtD
Dapagliflozin—Urticaria—Topotecan—peripheral nervous system neoplasm	0.000275	0.00192	CcSEcCtD
Dapagliflozin—Body temperature increased—Topotecan—peripheral nervous system neoplasm	0.000274	0.00191	CcSEcCtD
Dapagliflozin—Urticaria—Tretinoin—peripheral nervous system neoplasm	0.000273	0.00191	CcSEcCtD
Dapagliflozin—Urticaria—Isotretinoin—peripheral nervous system neoplasm	0.000273	0.00191	CcSEcCtD
Dapagliflozin—Malnutrition—Cisplatin—peripheral nervous system neoplasm	0.000272	0.0019	CcSEcCtD
Dapagliflozin—Body temperature increased—Isotretinoin—peripheral nervous system neoplasm	0.000272	0.0019	CcSEcCtD
Dapagliflozin—Body temperature increased—Tretinoin—peripheral nervous system neoplasm	0.000272	0.0019	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Alitretinoin—peripheral nervous system neoplasm	0.00027	0.00188	CcSEcCtD
Dapagliflozin—Urticaria—Melphalan—peripheral nervous system neoplasm	0.000269	0.00188	CcSEcCtD
Dapagliflozin—Phlebitis—Epirubicin—peripheral nervous system neoplasm	0.000269	0.00188	CcSEcCtD
Dapagliflozin—Discomfort—Alitretinoin—peripheral nervous system neoplasm	0.000268	0.00187	CcSEcCtD
Dapagliflozin—Neoplasm—Doxorubicin—peripheral nervous system neoplasm	0.000267	0.00187	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Epirubicin—peripheral nervous system neoplasm	0.000267	0.00186	CcSEcCtD
Dapagliflozin—Hypertension—Vincristine—peripheral nervous system neoplasm	0.000265	0.00185	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Alitretinoin—peripheral nervous system neoplasm	0.00026	0.00182	CcSEcCtD
Dapagliflozin—Oedema—Alitretinoin—peripheral nervous system neoplasm	0.00026	0.00182	CcSEcCtD
Dapagliflozin—Infection—Alitretinoin—peripheral nervous system neoplasm	0.000259	0.00181	CcSEcCtD
Dapagliflozin—Hypersensitivity—Topotecan—peripheral nervous system neoplasm	0.000255	0.00178	CcSEcCtD
Dapagliflozin—Hypersensitivity—Tretinoin—peripheral nervous system neoplasm	0.000253	0.00177	CcSEcCtD
Dapagliflozin—Hypersensitivity—Isotretinoin—peripheral nervous system neoplasm	0.000253	0.00177	CcSEcCtD
Dapagliflozin—Skin disorder—Alitretinoin—peripheral nervous system neoplasm	0.000253	0.00177	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Alitretinoin—peripheral nervous system neoplasm	0.000252	0.00176	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Vincristine—peripheral nervous system neoplasm	0.000251	0.00175	CcSEcCtD
Dapagliflozin—Oedema—Vincristine—peripheral nervous system neoplasm	0.000251	0.00175	CcSEcCtD
Dapagliflozin—Hypersensitivity—Melphalan—peripheral nervous system neoplasm	0.00025	0.00175	CcSEcCtD
Dapagliflozin—UGT2B4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000249	0.00585	CbGpPWpGaD
Dapagliflozin—Infection—Vincristine—peripheral nervous system neoplasm	0.000249	0.00174	CcSEcCtD
Dapagliflozin—Phlebitis—Doxorubicin—peripheral nervous system neoplasm	0.000249	0.00174	CcSEcCtD
Dapagliflozin—SLC5A4—Disease—GNS—peripheral nervous system neoplasm	0.000249	0.00583	CbGpPWpGaD
Dapagliflozin—Diabetes mellitus—Doxorubicin—peripheral nervous system neoplasm	0.000247	0.00172	CcSEcCtD
Dapagliflozin—Hypotension—Alitretinoin—peripheral nervous system neoplasm	0.000243	0.0017	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Vincristine—peripheral nervous system neoplasm	0.000243	0.00169	CcSEcCtD
Dapagliflozin—Back pain—Etoposide—peripheral nervous system neoplasm	0.000241	0.00168	CcSEcCtD
Dapagliflozin—SLC5A11—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	0.000239	0.00561	CbGpPWpGaD
Dapagliflozin—Hypoglycaemia—Epirubicin—peripheral nervous system neoplasm	0.000238	0.00166	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Epirubicin—peripheral nervous system neoplasm	0.000237	0.00165	CcSEcCtD
Dapagliflozin—SLC5A11—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	0.000235	0.00551	CbGpPWpGaD
Dapagliflozin—Hypotension—Vincristine—peripheral nervous system neoplasm	0.000234	0.00164	CcSEcCtD
Dapagliflozin—Hyponatraemia—Epirubicin—peripheral nervous system neoplasm	0.000233	0.00163	CcSEcCtD
Dapagliflozin—Pain in extremity—Epirubicin—peripheral nervous system neoplasm	0.000232	0.00162	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—peripheral nervous system neoplasm	0.00023	0.00161	CcSEcCtD
Dapagliflozin—Dizziness—Topotecan—peripheral nervous system neoplasm	0.000229	0.0016	CcSEcCtD
Dapagliflozin—Discomfort—Cisplatin—peripheral nervous system neoplasm	0.000229	0.0016	CcSEcCtD
Dapagliflozin—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.000227	0.00159	CcSEcCtD
Dapagliflozin—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.000227	0.00159	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	0.000225	0.00157	CcSEcCtD
Dapagliflozin—Constipation—Alitretinoin—peripheral nervous system neoplasm	0.000223	0.00156	CcSEcCtD
Dapagliflozin—Body temperature increased—Dactinomycin—peripheral nervous system neoplasm	0.000222	0.00155	CcSEcCtD
Dapagliflozin—Oedema—Cisplatin—peripheral nervous system neoplasm	0.000222	0.00155	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Cisplatin—peripheral nervous system neoplasm	0.000222	0.00155	CcSEcCtD
Dapagliflozin—Infection—Cisplatin—peripheral nervous system neoplasm	0.00022	0.00154	CcSEcCtD
Dapagliflozin—Hypoglycaemia—Doxorubicin—peripheral nervous system neoplasm	0.00022	0.00154	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Doxorubicin—peripheral nervous system neoplasm	0.000219	0.00153	CcSEcCtD
Dapagliflozin—Rash—Topotecan—peripheral nervous system neoplasm	0.000218	0.00153	CcSEcCtD
Dapagliflozin—SLC5A2—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000218	0.00512	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000218	0.00512	CbGpPWpGaD
Dapagliflozin—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.000218	0.00152	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Epirubicin—peripheral nervous system neoplasm	0.000217	0.00152	CcSEcCtD
Dapagliflozin—SLC5A4—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	0.000217	0.00509	CbGpPWpGaD
Dapagliflozin—Headache—Topotecan—peripheral nervous system neoplasm	0.000217	0.00152	CcSEcCtD
Dapagliflozin—Rash—Isotretinoin—peripheral nervous system neoplasm	0.000217	0.00151	CcSEcCtD
Dapagliflozin—Rash—Tretinoin—peripheral nervous system neoplasm	0.000217	0.00151	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.000217	0.00151	CcSEcCtD
Dapagliflozin—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.000216	0.00151	CcSEcCtD
Dapagliflozin—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.000216	0.00151	CcSEcCtD
Dapagliflozin—Dehydration—Epirubicin—peripheral nervous system neoplasm	0.000216	0.00151	CcSEcCtD
Dapagliflozin—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.000216	0.00151	CcSEcCtD
Dapagliflozin—Hyponatraemia—Doxorubicin—peripheral nervous system neoplasm	0.000215	0.0015	CcSEcCtD
Dapagliflozin—Headache—Tretinoin—peripheral nervous system neoplasm	0.000215	0.0015	CcSEcCtD
Dapagliflozin—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000215	0.0015	CcSEcCtD
Dapagliflozin—Hypertension—Etoposide—peripheral nervous system neoplasm	0.000215	0.0015	CcSEcCtD
Dapagliflozin—Constipation—Vincristine—peripheral nervous system neoplasm	0.000215	0.0015	CcSEcCtD
Dapagliflozin—Pain in extremity—Doxorubicin—peripheral nervous system neoplasm	0.000215	0.0015	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Cisplatin—peripheral nervous system neoplasm	0.000215	0.0015	CcSEcCtD
Dapagliflozin—Rash—Melphalan—peripheral nervous system neoplasm	0.000214	0.00149	CcSEcCtD
Dapagliflozin—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000214	0.00149	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Epirubicin—peripheral nervous system neoplasm	0.000212	0.00148	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.000211	0.00147	CcSEcCtD
Dapagliflozin—Discomfort—Etoposide—peripheral nervous system neoplasm	0.00021	0.00146	CcSEcCtD
Dapagliflozin—SLC5A4—Metabolism—GNS—peripheral nervous system neoplasm	0.000208	0.00488	CbGpPWpGaD
Dapagliflozin—Hypotension—Cisplatin—peripheral nervous system neoplasm	0.000207	0.00145	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000207	0.00145	CcSEcCtD
Dapagliflozin—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.000207	0.00145	CcSEcCtD
Dapagliflozin—Urticaria—Alitretinoin—peripheral nervous system neoplasm	0.000207	0.00144	CcSEcCtD
Dapagliflozin—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000206	0.00144	CcSEcCtD
Dapagliflozin—Nausea—Topotecan—peripheral nervous system neoplasm	0.000206	0.00144	CcSEcCtD
Dapagliflozin—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000204	0.00143	CcSEcCtD
Dapagliflozin—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000204	0.00143	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Etoposide—peripheral nervous system neoplasm	0.000203	0.00142	CcSEcCtD
Dapagliflozin—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—HSD17B12—peripheral nervous system neoplasm	0.000202	0.00474	CbGpPWpGaD
Dapagliflozin—Infection—Etoposide—peripheral nervous system neoplasm	0.000202	0.00141	CcSEcCtD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—NF1—peripheral nervous system neoplasm	0.000202	0.00472	CbGpPWpGaD
Dapagliflozin—Nausea—Melphalan—peripheral nervous system neoplasm	0.000201	0.00141	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Doxorubicin—peripheral nervous system neoplasm	0.000201	0.0014	CcSEcCtD
Dapagliflozin—Influenza—Epirubicin—peripheral nervous system neoplasm	0.0002	0.0014	CcSEcCtD
Dapagliflozin—SLC5A4—Metabolism—NME1—peripheral nervous system neoplasm	0.0002	0.00468	CbGpPWpGaD
Dapagliflozin—Dehydration—Doxorubicin—peripheral nervous system neoplasm	0.0002	0.00139	CcSEcCtD
Dapagliflozin—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000198	0.00139	CcSEcCtD
Dapagliflozin—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000197	0.00138	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.000197	0.00137	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000196	0.00137	CcSEcCtD
Dapagliflozin—Angina pectoris—Epirubicin—peripheral nervous system neoplasm	0.000195	0.00136	CcSEcCtD
Dapagliflozin—SLC5A4—Metabolism—COX2—peripheral nervous system neoplasm	0.000192	0.00451	CbGpPWpGaD
Dapagliflozin—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000192	0.00134	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000192	0.00134	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000192	0.00134	CcSEcCtD
Dapagliflozin—Hypotension—Etoposide—peripheral nervous system neoplasm	0.00019	0.00133	CcSEcCtD
Dapagliflozin—SLC5A2—Disease—GNS—peripheral nervous system neoplasm	0.000188	0.00442	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—GNS—peripheral nervous system neoplasm	0.000188	0.00442	CbGpPWpGaD
Dapagliflozin—Dysuria—Epirubicin—peripheral nervous system neoplasm	0.000187	0.00131	CcSEcCtD
Dapagliflozin—Influenza—Doxorubicin—peripheral nervous system neoplasm	0.000185	0.00129	CcSEcCtD
Dapagliflozin—Pollakiuria—Epirubicin—peripheral nervous system neoplasm	0.000185	0.00129	CcSEcCtD
Dapagliflozin—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000185	0.00129	CcSEcCtD
Dapagliflozin—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—peripheral nervous system neoplasm	0.000183	0.00429	CbGpPWpGaD
Dapagliflozin—UGT1A9—PPAR Alpha Pathway—MYC—peripheral nervous system neoplasm	0.000183	0.00429	CbGpPWpGaD
Dapagliflozin—UGT2B7—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	0.000181	0.00424	CbGpPWpGaD
Dapagliflozin—Angina pectoris—Doxorubicin—peripheral nervous system neoplasm	0.000181	0.00126	CcSEcCtD
Dapagliflozin—Infestation—Epirubicin—peripheral nervous system neoplasm	0.000179	0.00125	CcSEcCtD
Dapagliflozin—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.000179	0.00125	CcSEcCtD
Dapagliflozin—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000177	0.00124	CcSEcCtD
Dapagliflozin—Renal failure—Epirubicin—peripheral nervous system neoplasm	0.000176	0.00123	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000176	0.00123	CcSEcCtD
Dapagliflozin—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000175	0.00122	CcSEcCtD
Dapagliflozin—SLC5A4—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	0.000175	0.0041	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—PPP3R1—peripheral nervous system neoplasm	0.000174	0.00408	CbGpPWpGaD
Dapagliflozin—Constipation—Etoposide—peripheral nervous system neoplasm	0.000174	0.00121	CcSEcCtD
Dapagliflozin—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.000174	0.00121	CcSEcCtD
Dapagliflozin—Dysuria—Doxorubicin—peripheral nervous system neoplasm	0.000173	0.00121	CcSEcCtD
Dapagliflozin—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000172	0.0012	CcSEcCtD
Dapagliflozin—SLC5A4—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	0.000171	0.00402	CbGpPWpGaD
Dapagliflozin—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	0.000171	0.0012	CcSEcCtD
Dapagliflozin—UGT2B4—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000169	0.00395	CbGpPWpGaD
Dapagliflozin—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.000167	0.00392	CbGpPWpGaD
Dapagliflozin—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000167	0.00117	CcSEcCtD
Dapagliflozin—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000166	0.00116	CcSEcCtD
Dapagliflozin—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	0.000165	0.00115	CcSEcCtD
Dapagliflozin—Infestation—Doxorubicin—peripheral nervous system neoplasm	0.000165	0.00115	CcSEcCtD
Dapagliflozin—SLC5A1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	0.000165	0.00386	CbGpPWpGaD
Dapagliflozin—SLC5A2—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	0.000165	0.00386	CbGpPWpGaD
Dapagliflozin—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000164	0.00115	CcSEcCtD
Dapagliflozin—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000164	0.00115	CcSEcCtD
Dapagliflozin—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000163	0.00114	CcSEcCtD
Dapagliflozin—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000163	0.00114	CcSEcCtD
Dapagliflozin—Renal failure—Doxorubicin—peripheral nervous system neoplasm	0.000163	0.00113	CcSEcCtD
Dapagliflozin—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000161	0.00113	CcSEcCtD
Dapagliflozin—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000161	0.00112	CcSEcCtD
Dapagliflozin—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000161	0.00112	CcSEcCtD
Dapagliflozin—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	0.000159	0.00374	CbGpPWpGaD
Dapagliflozin—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	0.000158	0.00111	CcSEcCtD
Dapagliflozin—Rash—Vincristine—peripheral nervous system neoplasm	0.000158	0.0011	CcSEcCtD
Dapagliflozin—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000158	0.0011	CcSEcCtD
Dapagliflozin—SLC5A2—Metabolism—GNS—peripheral nervous system neoplasm	0.000158	0.0037	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—GNS—peripheral nervous system neoplasm	0.000158	0.0037	CbGpPWpGaD
Dapagliflozin—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	0.000158	0.0011	CcSEcCtD
Dapagliflozin—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	0.000157	0.0011	CcSEcCtD
Dapagliflozin—Headache—Vincristine—peripheral nervous system neoplasm	0.000157	0.0011	CcSEcCtD
Dapagliflozin—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000155	0.00108	CcSEcCtD
Dapagliflozin—SLC5A1—Metabolism—NME1—peripheral nervous system neoplasm	0.000151	0.00355	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—NME1—peripheral nervous system neoplasm	0.000151	0.00355	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—ENO2—peripheral nervous system neoplasm	0.000151	0.00353	CbGpPWpGaD
Dapagliflozin—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.00015	0.00105	CcSEcCtD
Dapagliflozin—Nausea—Vincristine—peripheral nervous system neoplasm	0.000149	0.00104	CcSEcCtD
Dapagliflozin—UGT1A9—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	0.000147	0.00344	CbGpPWpGaD
Dapagliflozin—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	0.000147	0.00102	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	0.000146	0.00102	CcSEcCtD
Dapagliflozin—SLC5A1—Metabolism—COX2—peripheral nervous system neoplasm	0.000146	0.00341	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—COX2—peripheral nervous system neoplasm	0.000146	0.00341	CbGpPWpGaD
Dapagliflozin—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	0.000145	0.00102	CcSEcCtD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.00014	0.00328	CbGpPWpGaD
Dapagliflozin—Rash—Cisplatin—peripheral nervous system neoplasm	0.00014	0.000977	CcSEcCtD
Dapagliflozin—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.00014	0.000976	CcSEcCtD
Dapagliflozin—Malnutrition—Epirubicin—peripheral nervous system neoplasm	0.00014	0.000975	CcSEcCtD
Dapagliflozin—UGT2B7—NRF2 pathway—HGF—peripheral nervous system neoplasm	0.000138	0.00325	CbGpPWpGaD
Dapagliflozin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	0.000136	0.00319	CbGpPWpGaD
Dapagliflozin—Back pain—Epirubicin—peripheral nervous system neoplasm	0.000135	0.000943	CcSEcCtD
Dapagliflozin—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000134	0.000939	CcSEcCtD
Dapagliflozin—SLC5A2—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	0.000132	0.0031	CbGpPWpGaD
Dapagliflozin—SLC5A1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	0.000132	0.0031	CbGpPWpGaD
Dapagliflozin—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000132	0.00092	CcSEcCtD
Dapagliflozin—SLC5A2—Disease—PPP3R1—peripheral nervous system neoplasm	0.000132	0.00309	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—PPP3R1—peripheral nervous system neoplasm	0.000132	0.00309	CbGpPWpGaD
Dapagliflozin—SLC5A2—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	0.00013	0.00305	CbGpPWpGaD
Dapagliflozin—SLC5A1—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	0.00013	0.00305	CbGpPWpGaD
Dapagliflozin—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	0.000129	0.000902	CcSEcCtD
Dapagliflozin—Rash—Etoposide—peripheral nervous system neoplasm	0.000128	0.000895	CcSEcCtD
Dapagliflozin—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000128	0.000894	CcSEcCtD
Dapagliflozin—Headache—Etoposide—peripheral nervous system neoplasm	0.000127	0.000889	CcSEcCtD
Dapagliflozin—ABCB1—HIF-1-alpha transcription factor network—SLC2A1—peripheral nervous system neoplasm	0.000127	0.00298	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—ENO2—peripheral nervous system neoplasm	0.000126	0.00296	CbGpPWpGaD
Dapagliflozin—Back pain—Doxorubicin—peripheral nervous system neoplasm	0.000125	0.000873	CcSEcCtD
Dapagliflozin—UGT2B4—Metabolism—GNS—peripheral nervous system neoplasm	0.000122	0.00286	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—SLC2A1—peripheral nervous system neoplasm	0.000121	0.00285	CbGpPWpGaD
Dapagliflozin—Nausea—Etoposide—peripheral nervous system neoplasm	0.000121	0.000843	CcSEcCtD
Dapagliflozin—Hypertension—Epirubicin—peripheral nervous system neoplasm	0.000121	0.000842	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000118	0.000824	CcSEcCtD
Dapagliflozin—Discomfort—Epirubicin—peripheral nervous system neoplasm	0.000117	0.00082	CcSEcCtD
Dapagliflozin—UGT2B4—Metabolism—NME1—peripheral nervous system neoplasm	0.000117	0.00274	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—ENO2—peripheral nervous system neoplasm	0.000114	0.00268	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—ENO2—peripheral nervous system neoplasm	0.000114	0.00268	CbGpPWpGaD
Dapagliflozin—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	0.000114	0.000796	CcSEcCtD
Dapagliflozin—Oedema—Epirubicin—peripheral nervous system neoplasm	0.000114	0.000796	CcSEcCtD
Dapagliflozin—UGT2B7—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000114	0.00266	CbGpPWpGaD
Dapagliflozin—Infection—Epirubicin—peripheral nervous system neoplasm	0.000113	0.000791	CcSEcCtD
Dapagliflozin—CYP2A6—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	0.000113	0.00265	CbGpPWpGaD
Dapagliflozin—UGT1A9—NRF2 pathway—HGF—peripheral nervous system neoplasm	0.000113	0.00264	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—COX2—peripheral nervous system neoplasm	0.000112	0.00264	CbGpPWpGaD
Dapagliflozin—Hypertension—Doxorubicin—peripheral nervous system neoplasm	0.000112	0.000779	CcSEcCtD
Dapagliflozin—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.000111	0.000773	CcSEcCtD
Dapagliflozin—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.00011	0.00259	CbGpPWpGaD
Dapagliflozin—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	0.00011	0.000769	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.000109	0.000763	CcSEcCtD
Dapagliflozin—Discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000109	0.000759	CcSEcCtD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—NME1—peripheral nervous system neoplasm	0.000107	0.0025	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—BCHE—peripheral nervous system neoplasm	0.000107	0.0025	CbGpPWpGaD
Dapagliflozin—Hypotension—Epirubicin—peripheral nervous system neoplasm	0.000106	0.000744	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	0.000105	0.000736	CcSEcCtD
Dapagliflozin—Oedema—Doxorubicin—peripheral nervous system neoplasm	0.000105	0.000736	CcSEcCtD
Dapagliflozin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	0.000105	0.00246	CbGpPWpGaD
Dapagliflozin—Infection—Doxorubicin—peripheral nervous system neoplasm	0.000105	0.000732	CcSEcCtD
Dapagliflozin—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.000102	0.000715	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	0.000102	0.000712	CcSEcCtD
Dapagliflozin—SLC5A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	0.000102	0.00238	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—TH—peripheral nervous system neoplasm	0.0001	0.00235	CbGpPWpGaD
Dapagliflozin—Hypotension—Doxorubicin—peripheral nervous system neoplasm	9.85e-05	0.000688	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	9.84e-05	0.000687	CcSEcCtD
Dapagliflozin—Constipation—Epirubicin—peripheral nervous system neoplasm	9.74e-05	0.000681	CcSEcCtD
Dapagliflozin—CYP2A6—Fluoropyrimidine Activity—TP53—peripheral nervous system neoplasm	9.56e-05	0.00224	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—ENO2—peripheral nervous system neoplasm	9.56e-05	0.00224	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—ENO2—peripheral nervous system neoplasm	9.56e-05	0.00224	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PPIP5K2—peripheral nervous system neoplasm	9.23e-05	0.00216	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—SLC2A1—peripheral nervous system neoplasm	9.2e-05	0.00216	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—SLC2A1—peripheral nervous system neoplasm	9.2e-05	0.00216	CbGpPWpGaD
Dapagliflozin—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	9.1e-05	0.000636	CcSEcCtD
Dapagliflozin—Urticaria—Epirubicin—peripheral nervous system neoplasm	9.05e-05	0.000632	CcSEcCtD
Dapagliflozin—Constipation—Doxorubicin—peripheral nervous system neoplasm	9.02e-05	0.00063	CcSEcCtD
Dapagliflozin—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	9.01e-05	0.000629	CcSEcCtD
Dapagliflozin—CYP2A6—NRF2 pathway—HGF—peripheral nervous system neoplasm	8.67e-05	0.00203	CbGpPWpGaD
Dapagliflozin—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	8.4e-05	0.000586	CcSEcCtD
Dapagliflozin—Urticaria—Doxorubicin—peripheral nervous system neoplasm	8.38e-05	0.000585	CcSEcCtD
Dapagliflozin—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	8.34e-05	0.000582	CcSEcCtD
Dapagliflozin—SLC5A4—Metabolism—GNAS—peripheral nervous system neoplasm	8.18e-05	0.00192	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—BCHE—peripheral nervous system neoplasm	8.08e-05	0.00189	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—BCHE—peripheral nervous system neoplasm	8.08e-05	0.00189	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	8.04e-05	0.00189	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—ABCB1—peripheral nervous system neoplasm	8.03e-05	0.00188	CbGpPWpGaD
Dapagliflozin—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	7.77e-05	0.000542	CcSEcCtD
Dapagliflozin—SLC5A1—Metabolism—SLC2A1—peripheral nervous system neoplasm	7.71e-05	0.00181	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—SLC2A1—peripheral nervous system neoplasm	7.71e-05	0.00181	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—HSD17B12—peripheral nervous system neoplasm	7.68e-05	0.0018	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—TH—peripheral nervous system neoplasm	7.6e-05	0.00178	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—TH—peripheral nervous system neoplasm	7.6e-05	0.00178	CbGpPWpGaD
Dapagliflozin—Dizziness—Epirubicin—peripheral nervous system neoplasm	7.54e-05	0.000526	CcSEcCtD
Dapagliflozin—UGT2B4—Metabolism—ENO2—peripheral nervous system neoplasm	7.38e-05	0.00173	CbGpPWpGaD
Dapagliflozin—Rash—Epirubicin—peripheral nervous system neoplasm	7.18e-05	0.000502	CcSEcCtD
Dapagliflozin—Dermatitis—Epirubicin—peripheral nervous system neoplasm	7.18e-05	0.000501	CcSEcCtD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—NRAS—peripheral nervous system neoplasm	7.14e-05	0.00167	CbGpPWpGaD
Dapagliflozin—Headache—Epirubicin—peripheral nervous system neoplasm	7.14e-05	0.000499	CcSEcCtD
Dapagliflozin—CYP2A6—Metabolism—PPIP5K2—peripheral nervous system neoplasm	7.12e-05	0.00167	CbGpPWpGaD
Dapagliflozin—Dizziness—Doxorubicin—peripheral nervous system neoplasm	6.97e-05	0.000487	CcSEcCtD
Dapagliflozin—SLC5A4—Disease—PTPN11—peripheral nervous system neoplasm	6.79e-05	0.00159	CbGpPWpGaD
Dapagliflozin—Nausea—Epirubicin—peripheral nervous system neoplasm	6.77e-05	0.000473	CcSEcCtD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—MYC—peripheral nervous system neoplasm	6.65e-05	0.00156	CbGpPWpGaD
Dapagliflozin—Rash—Doxorubicin—peripheral nervous system neoplasm	6.65e-05	0.000464	CcSEcCtD
Dapagliflozin—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	6.64e-05	0.000464	CcSEcCtD
Dapagliflozin—Headache—Doxorubicin—peripheral nervous system neoplasm	6.61e-05	0.000461	CcSEcCtD
Dapagliflozin—Nausea—Doxorubicin—peripheral nervous system neoplasm	6.26e-05	0.000437	CcSEcCtD
Dapagliflozin—UGT1A9—Metabolism—HSD17B12—peripheral nervous system neoplasm	6.24e-05	0.00146	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—BCHE—peripheral nervous system neoplasm	6.24e-05	0.00146	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—GNAS—peripheral nervous system neoplasm	6.2e-05	0.00145	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—GNAS—peripheral nervous system neoplasm	6.2e-05	0.00145	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—ABCB1—peripheral nervous system neoplasm	6.08e-05	0.00143	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—ABCB1—peripheral nervous system neoplasm	6.08e-05	0.00143	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	6e-05	0.00141	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.95e-05	0.00139	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—TH—peripheral nervous system neoplasm	5.86e-05	0.00137	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—GNS—peripheral nervous system neoplasm	5.55e-05	0.0013	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—ERBB2—peripheral nervous system neoplasm	5.37e-05	0.00126	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—NME1—peripheral nervous system neoplasm	5.32e-05	0.00125	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	5.3e-05	0.00124	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—peripheral nervous system neoplasm	5.23e-05	0.00123	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—peripheral nervous system neoplasm	5.22e-05	0.00122	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	5.18e-05	0.00122	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—PTPN11—peripheral nervous system neoplasm	5.15e-05	0.00121	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—PTPN11—peripheral nervous system neoplasm	5.15e-05	0.00121	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	5.13e-05	0.0012	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—COX2—peripheral nervous system neoplasm	5.12e-05	0.0012	CbGpPWpGaD
Dapagliflozin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—peripheral nervous system neoplasm	5.05e-05	0.00118	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—HSD17B12—peripheral nervous system neoplasm	4.81e-05	0.00113	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—GNAS—peripheral nervous system neoplasm	4.79e-05	0.00112	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	4.76e-05	0.00112	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—ABCB1—peripheral nervous system neoplasm	4.7e-05	0.0011	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—peripheral nervous system neoplasm	4.55e-05	0.00107	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—GNS—peripheral nervous system neoplasm	4.51e-05	0.00106	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—CASP3—peripheral nervous system neoplasm	4.42e-05	0.00104	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	4.36e-05	0.00102	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—NME1—peripheral nervous system neoplasm	4.32e-05	0.00101	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—MYC—peripheral nervous system neoplasm	4.24e-05	0.000994	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	4.24e-05	0.000993	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—COX2—peripheral nervous system neoplasm	4.16e-05	0.000976	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—NRAS—peripheral nervous system neoplasm	4.08e-05	0.000957	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	4.08e-05	0.000956	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—ERBB2—peripheral nervous system neoplasm	4.07e-05	0.000953	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—ERBB2—peripheral nervous system neoplasm	4.07e-05	0.000953	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PPIP5K2—peripheral nervous system neoplasm	3.99e-05	0.000936	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PPIP5K2—peripheral nervous system neoplasm	3.96e-05	0.000928	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—MYC—peripheral nervous system neoplasm	3.8e-05	0.000891	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—HSD17B12—peripheral nervous system neoplasm	3.58e-05	0.00084	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—GNS—peripheral nervous system neoplasm	3.48e-05	0.000815	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	3.38e-05	0.000793	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—ENO2—peripheral nervous system neoplasm	3.36e-05	0.000788	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—NME1—peripheral nervous system neoplasm	3.33e-05	0.000781	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—peripheral nervous system neoplasm	3.33e-05	0.000781	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—COX2—peripheral nervous system neoplasm	3.21e-05	0.000752	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—NRAS—peripheral nervous system neoplasm	3.09e-05	0.000725	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—NRAS—peripheral nervous system neoplasm	3.09e-05	0.000725	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—HRAS—peripheral nervous system neoplasm	2.99e-05	0.0007	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	2.98e-05	0.000698	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—MYC—peripheral nervous system neoplasm	2.88e-05	0.000676	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—MYC—peripheral nervous system neoplasm	2.88e-05	0.000676	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.86e-05	0.000671	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—BCHE—peripheral nervous system neoplasm	2.84e-05	0.000666	CbGpPWpGaD
Dapagliflozin—ABCB1—HIF-1-alpha transcription factor network—AKT1—peripheral nervous system neoplasm	2.76e-05	0.000647	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—ENO2—peripheral nervous system neoplasm	2.73e-05	0.000641	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.71e-05	0.000635	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.7e-05	0.000632	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.67e-05	0.000627	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—TH—peripheral nervous system neoplasm	2.67e-05	0.000626	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—AKT1—peripheral nervous system neoplasm	2.64e-05	0.000618	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	2.61e-05	0.000612	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GNS—peripheral nervous system neoplasm	2.59e-05	0.000607	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—NME1—peripheral nervous system neoplasm	2.48e-05	0.000582	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	2.4e-05	0.000563	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—COX2—peripheral nervous system neoplasm	2.39e-05	0.00056	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—BCHE—peripheral nervous system neoplasm	2.31e-05	0.000541	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.28e-05	0.000536	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—HRAS—peripheral nervous system neoplasm	2.26e-05	0.000531	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—HRAS—peripheral nervous system neoplasm	2.26e-05	0.000531	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	2.22e-05	0.000521	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—AKT1—peripheral nervous system neoplasm	2.21e-05	0.000518	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.2e-05	0.000516	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—GNAS—peripheral nervous system neoplasm	2.18e-05	0.000511	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	2.18e-05	0.000511	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—TH—peripheral nervous system neoplasm	2.17e-05	0.000509	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	2.16e-05	0.000506	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—ABCB1—peripheral nervous system neoplasm	2.14e-05	0.000502	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—ENO2—peripheral nervous system neoplasm	2.11e-05	0.000494	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GNS—peripheral nervous system neoplasm	2.07e-05	0.000485	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—AKT1—peripheral nervous system neoplasm	2e-05	0.000469	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—AKT1—peripheral nervous system neoplasm	2e-05	0.000469	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—NME1—peripheral nervous system neoplasm	1.98e-05	0.000465	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GNS—peripheral nervous system neoplasm	1.95e-05	0.000457	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GNS—peripheral nervous system neoplasm	1.93e-05	0.000453	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—COX2—peripheral nervous system neoplasm	1.91e-05	0.000448	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	1.9e-05	0.000445	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—NME1—peripheral nervous system neoplasm	1.87e-05	0.000438	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—NME1—peripheral nervous system neoplasm	1.85e-05	0.000434	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—COX2—peripheral nervous system neoplasm	1.8e-05	0.000422	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—COX2—peripheral nervous system neoplasm	1.78e-05	0.000418	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—BCHE—peripheral nervous system neoplasm	1.78e-05	0.000417	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—GNAS—peripheral nervous system neoplasm	1.77e-05	0.000415	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.76e-05	0.000413	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—ABCB1—peripheral nervous system neoplasm	1.74e-05	0.000408	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	1.74e-05	0.000407	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	1.7e-05	0.000399	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.7e-05	0.000398	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—AKT1—peripheral nervous system neoplasm	1.67e-05	0.000392	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—AKT1—peripheral nervous system neoplasm	1.67e-05	0.000392	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—TH—peripheral nervous system neoplasm	1.67e-05	0.000392	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GNS—peripheral nervous system neoplasm	1.65e-05	0.000387	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—NME1—peripheral nervous system neoplasm	1.58e-05	0.000371	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ENO2—peripheral nervous system neoplasm	1.57e-05	0.000368	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—COX2—peripheral nervous system neoplasm	1.52e-05	0.000357	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	1.4e-05	0.000328	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—GNAS—peripheral nervous system neoplasm	1.37e-05	0.00032	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—ABCB1—peripheral nervous system neoplasm	1.34e-05	0.000314	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—BCHE—peripheral nervous system neoplasm	1.33e-05	0.000311	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—AKT1—peripheral nervous system neoplasm	1.29e-05	0.000303	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	1.27e-05	0.000299	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.26e-05	0.000297	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ENO2—peripheral nervous system neoplasm	1.25e-05	0.000294	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—TH—peripheral nervous system neoplasm	1.25e-05	0.000292	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	1.22e-05	0.000286	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ENO2—peripheral nervous system neoplasm	1.18e-05	0.000277	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	1.18e-05	0.000277	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	1.18e-05	0.000276	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ENO2—peripheral nervous system neoplasm	1.17e-05	0.000274	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—BCHE—peripheral nervous system neoplasm	1.06e-05	0.000248	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GNAS—peripheral nervous system neoplasm	1.02e-05	0.000239	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.01e-05	0.000237	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ENO2—peripheral nervous system neoplasm	1e-05	0.000235	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ABCB1—peripheral nervous system neoplasm	9.99e-06	0.000234	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—BCHE—peripheral nervous system neoplasm	9.98e-06	0.000234	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—TH—peripheral nervous system neoplasm	9.96e-06	0.000233	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—BCHE—peripheral nervous system neoplasm	9.89e-06	0.000232	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—SLC2A1—peripheral nervous system neoplasm	9.52e-06	0.000223	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—SLC2A1—peripheral nervous system neoplasm	9.44e-06	0.000221	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—TH—peripheral nervous system neoplasm	9.38e-06	0.00022	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—TH—peripheral nervous system neoplasm	9.3e-06	0.000218	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—BCHE—peripheral nervous system neoplasm	8.45e-06	0.000198	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GNAS—peripheral nervous system neoplasm	8.13e-06	0.000191	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—SLC2A1—peripheral nervous system neoplasm	8.06e-06	0.000189	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—TH—peripheral nervous system neoplasm	7.95e-06	0.000186	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	7.72e-06	0.000181	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GNAS—peripheral nervous system neoplasm	7.66e-06	0.00018	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GNAS—peripheral nervous system neoplasm	7.59e-06	0.000178	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ABCB1—peripheral nervous system neoplasm	7.52e-06	0.000176	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ABCB1—peripheral nervous system neoplasm	7.45e-06	0.000175	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	6.52e-06	0.000153	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GNAS—peripheral nervous system neoplasm	6.49e-06	0.000152	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ABCB1—peripheral nervous system neoplasm	6.37e-06	0.000149	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.22e-06	0.000146	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	6.13e-06	0.000144	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—AKT1—peripheral nervous system neoplasm	5.89e-06	0.000138	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	5.01e-06	0.000117	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	4.91e-06	0.000115	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—AKT1—peripheral nervous system neoplasm	4.78e-06	0.000112	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—AKT1—peripheral nervous system neoplasm	3.69e-06	8.64e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—AKT1—peripheral nervous system neoplasm	2.75e-06	6.44e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—AKT1—peripheral nervous system neoplasm	2.19e-06	5.14e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—AKT1—peripheral nervous system neoplasm	2.07e-06	4.85e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—AKT1—peripheral nervous system neoplasm	2.05e-06	4.81e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—AKT1—peripheral nervous system neoplasm	1.75e-06	4.11e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	1.35e-06	3.17e-05	CbGpPWpGaD
